Novartis announced plans to construct a flagship manufacturing hub in North Carolina as part of a $23 billion U.S. infrastructure investment over five years. The project will add biologics manufacturing, sterile packaging, and solid‑dosage capabilities across new and expanded sites in Durham and Morrisville, with expected openings in 2027–2028. Novartis said the hub will support end‑to‑end production for key medicines including cell and gene therapies, radioligand therapies and xRNA modalities, creating roughly 700 direct jobs and over 3,000 indirect roles by 2030. CEO Vas Narasimhan framed the build as bolstering U.S. supply‑chain resilience and capacity for advanced therapeutic manufacturing.